Document:

Exhibit 10.24

                AMENDMENT NO. 1 TO EXCLUSIVE SUBLICENSE AGREEMENT

      This Amendment No. 1 is made to the Exclusive Sublicense Agreement made
December 9, 2003, ("the Agreement") by and between Luitpold Pharmaceuticals,
Inc., a New York corporation ("Luitpold") and BioMimetic Therapeutics,
Inc.(formerly BioMimetic Pharmaceuticals, Inc.), a Delaware corporation ("BMTI")
(each, individually a "Party" and collectively, the "Parties") as of this 21th
day of December, 2005.

      WHEREAS, the Term of the Agreement was to extend to December 31, 2014, or
until the last to expire valid patent claim in a country; and

      WHEREAS, the Parties have agreed to extend the Term of the Agreement;

      NOW, THEREFORE, in consideration of the mutual premises, covenants, and
agreements hereinafter set forth, the sufficiency of which is hereby
acknowledged, the Parties to the Agreement, intending to be bound, mutually
agree as follows:

      1.    Section 3.1 of the Agreement is amended as follows:

            "The term of this Agreement shall be for a period beginning on the
            Effective Date and shall continue until December 31, 2026. By no
            later than December 31, 2025, Luitpold shall have the right to
            extend the term of this Agreement for a period of five (5) years by
            notice to BMTI and thereafter it shall have the right to extend the
            term for additional five (5) year terms upon one (1) year's notice
            to BMTI. If extended, Section 4.3, among other provisions, survives
            for so long as Luitpold relies upon Know-how, trademarks, trade
            secrets and/or other proprietary technology or information developed
            by BMPI."

      2.    Except as otherwise expressly amended above, all provisions of the
Agreement shall continue to remain in full force and effect.

      IN WITNESS WHEREOF, Luitpold and BMTI have entered into this Amendment No.
1 effective as of the date hereinabove written, each by a duly authorized
officer, in duplicate originals.

LUITPOLD PHARMACEUTICALS, INC.                  BIOMIMETIC THERAPEUTICS, INC.

By:/s/ Mary Jane Helenek                        By:/s/ Samuel Lynch
   ------------------------------------------      -------------------------
       Mary Jane Helenek, R. Ph., M.S., M.B.A.         Samuel Lynch, D.D.S.
       President abd CEO                               President and CEO

                                      - 2 -Exhibit 10.25

                               AMENDMENT NO. 1 TO
                        MANUFACTURE AND SUPPLY AGREEMENT

      This Amendment No. 1 is made to the Manufacture and Supply Agreement made
December 9, 2003, ("the Agreement") by and between Luitpold Pharmaceuticals,
Inc., a New York corporation ("Luitpold") and BioMimetic Therapeutics, Inc.
(formerly BioMimetic Pharmaceuticals, Inc.), a Delaware corporation ("BMTI")
(each, individually a "Party" and collectively, the "Parties") as of this 21th
day of December, 2005.

      WHEREAS, the Term of the Agreement was to extend until the seventh
anniversary date of the Effective Date of the Agreement; and

      WHEREAS, the Parties have agreed to extend the Term of the Agreement;

      NOW, THEREFORE, in consideration of the mutual premises, covenants, and
agreements hereinafter set forth, the sufficiency of which is hereby
acknowledged, the Parties to the Agreement, intending to be bound, mutually
agree as follows:

      1.    Section 11.1 of the Agreement is amended as follows:

            "The term of this Agreement shall be for a period beginning on the
            Effective Date and shall continue until December 31, 2026 (the
            "Initial Term"). This Agreement shall renew at the end of the
            Initial Term for subsequent five (5) year renewal terms (each, a
            "Renewal Term," and together with the Initial Term, the "Term"),
            unless either party gives at least six (6) months notice of intent
            not to renew."

      2.    Except as otherwise expressly amended above, all provisions of the
Agreement shall continue to remain in full force and effect.

      IN WITNESS WHEREOF, Luitpold and BMTI have entered into this Amendment No.
1 effective as of the date hereinabove written, each by a duly authorized
officer, in duplicate originals.

LUITPOLD PHARMACEUTICALS, INC.                   BIOMIMETIC THERAPEUTICS, INC.

By:/s/ Mary Jane Helenek                         By:/s/ Samuel Lynch
   -------------------------------------------      ------------------------
       Mary Jane Helenek, R. Ph., M.S., M.B.A.          Samuel Lynch, D.D.S.
       Preisedent and CEO                               President and CEO

                                      - 2 -Exhibit 10.26

BIOMIMETIC
--------------------------------------------------------------------------------
THERAPEUTICS

December 21, 2005

Mary Jane Helenek, R.Ph., M.S., M.B.A.
President and CEO
Luitpold Pharmaceuticals, Inc.
One Luitpold Drive
Shirley, NY 11967

Re:   Transfer Price Adjustment for
      GEM 21S(R) Growth-factor Enhanced Matrix

Dear Mary Jane:

In accordance with Section 4.3 of our December 9, 2003 Manufacturing and Supply
Agreement ("MSA") and the ongoing discussions with which we have had, effective
immediately with the next shipment received the price of the Licensed Products
under our MSA is hereby adjusted to ** per Unit for 2006 (ie no additional
increase for 2006). In addition, BioMimetic agrees to provide Luitpold with a
volume discount that will apply to purchases made after **. In view of the
upcoming holidays, we will provide you with a specific proposal regarding the
volume discount shortly after the first of the year.

In addition, BioMimetic agrees to use its best efforts to:

      (1) work with Luitpold to reach an agreement under which title to the
      Licensed Products will transfer to Luitpold in New York, provided that
      Luitpold continues to be responsible for the current shipping costs and
      risks; and

      (2) continue with the currently planned stability studies that our staffs
      discussed during their conference call yesterday and the requisite
      regulatory filings that will permit room temperature shipping of the
      Licensed Products.

Finally, as we discussed earlier today, if we ultimately enter into a
manufacturing agreement under which Luitpold assumes responsibility for the
final stages of our manufacturing process, Luitpold should realize a significant
savings in its shipping

--------------------------------------------------------------------------------
   BioMimetic Therapeutics, Inc.  389-A Nichol Mill Lane, Franklin, TN 37067
                  Phone 615-844-1280   www.biomimetics.com

**  REPRESENTS MATERIAL WHICH HAS BEEN REDACTED AND SEPARATELY FILED WITH THE
    SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
    TREATMENT PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

Mary Jane Helenek, R.Ph., M.S., M.B.A.
December 21, 2005
Page 2

expenses. Such savings shall be maintained by Luitpold, and BioMimetic does not
expect to share in those savings.

Please acknowledge this price adjustment by countersigning this letter and
returning a copy to me.

Best regards,

/s/ Samuel E. Lynch
------------------------
Samuel E. Lynch, D.M.D., D.M.Sc.
President & CEO

cc:   Dr. Charles Hart
      Peter S. Reichertz

AGREED AND ACKNOWLEDGED:

/s/ Mary Jane Helenek
------------------------Exhibit 10.27

                            INDEMNIFICATION AGREEMENT

         This INDEMNIFICATION AGREEMENT (this "Agreement") is made and entered
into this ____ day of _____________, 2005 (the "Effective Date") by and between
BioMimetics Therapeutics, Inc., a Delaware corporation (the "Company"), and [ ]
(the "Indemnitee").

         WHEREAS, the Company believes it is essential to retain and attract
qualified directors and officers;

         WHEREAS, the Indemnitee is a director and/or officer of the Company;

         WHEREAS, both the Company and the Indemnitee recognize the increased
risk of litigation and other claims being asserted against directors and
officers of public companies;

         WHEREAS, the Company's Amended and Restated Certificate of
Incorporation (the "Certificate of Incorporation") and Bylaws (the "Bylaws")
authorize the Company to indemnify and advance expenses to its directors and
officers to the extent permitted by the DGCL (as hereinafter defined);

         WHEREAS, the Indemnitee has been serving and intends to continue
serving as a director and/or officer of the Company in part in reliance on the
Certificate of Incorporation and Bylaws, or is relying upon the rights afforded
under this Agreement in accepting the Indemnitee's position as a director,
officer or employee of the Company; and

         WHEREAS, in recognition of the Indemnitee's need for (i) substantial
protection against personal liability based on the Indemnitee's reliance on the
Certificate of Incorporation and Bylaws, (ii) specific contractual assurance
that the protection promised by the Certificate of Incorporation and Bylaws will
be available to the Indemnitee, regardless of, among other things, any amendment
to or revocation of the Bylaws or any change in the composition of the Company's
Board of Directors (the "Board") or acquisition transaction relating to the
Company and (iii) an inducement to continue to provide effective services to the
Company as a director and/or officer thereof, the Company wishes to provide for
the indemnification of the Indemnitee and to advance expenses to the Indemnitee
to the fullest extent permitted by law and as set forth in this Agreement, and,
to the extent insurance is maintained by the Company, to provide for the
continued coverage of the Indemnitee under the Company's directors' and
officers' liability insurance policies.

         NOW, THEREFORE, in consideration of the premises contained herein and
for the Indemnitee continuing to serve the Company directly or, at its request,
with another enterprise, and intending to be legally bound hereby, the parties
hereto agree as follows:

1.       CERTAIN DEFINITIONS.

             (a)      A "Change in Control" shall be deemed to have occurred if:

                    (i) any "person," as such term is used in Sections 13(d) and
          14(d) of the Securities Exchange Act of 1934, as amended, and the
          rules and regulations thereunder (the "Exchange Act"), other than (a)
          a trustee or other fiduciary holding securities under an employee
          benefit plan of the Company; (b) a corporation owned, directly or
          indirectly, by the stockholders of the Company in substantially the
          same proportions as their ownership of stock of the Company; or (c)
          any current beneficial stockholder or group, as defined by Rule 13d-5
          under the Exchange Act, including the heirs, assigns and successors
          thereof, of beneficial ownership, within the meaning of Rule 13d-3
          under the Exchange Act, of securities possessing more than 50% of the
          total combined voting power of the Company's outstanding securities;
          hereafter becomes the "beneficial owner," as defined in Rule 13d-3
          under the Exchange Act, directly or indirectly, of securities of the
          Company representing 25% or more of the total combined voting power
          represented by the Company's then outstanding Voting Securities;

                    (ii) during any period of two consecutive years, individuals
          who at the beginning of such period constitute the Board and any new
          director whose election by the Board or nomination for election by the
          Company's stockholders was approved by a vote of at least majority of
          the directors then still in office who either were directors at the
          beginning of the period or whose election or nomination for election
          was previously so approved, cease for any reason to constitute a
          majority thereof; or

                    (iii) the stockholders of the Company approve a merger or
          consolidation of the Company with any other corporation, other than a
          merger or consolidation which would result in the Voting Securities of
          the Company outstanding immediately prior thereto continuing to
          represent (either by remaining outstanding or by being converted into
          Voting Securities of the surviving entity) at least 65% of the total
          voting power represented by the Voting Securities of the Company or
          such surviving entity outstanding immediately after such merger or
          consolidation, or the stockholders of the Company approve a plan of
          complete liquidation of the Company or an agreement for the sale or
          disposition by the Company, in one transaction or a series of
          transactions, of all or substantially all of the Company's assets.

          (b) "DGCL" shall mean the General Corporation Law of the State of
Delaware, as the same exists or may hereafter be amended or interpreted;
provided, however, that in the case of any such amendment or interpretation,
only to the extent that such amendment or interpretation permits the Company to
provide broader indemnification rights than were permitted prior thereto.

          (c) "Expense" shall mean attorneys' fees and all other costs, expenses
and obligations paid or incurred in connection with investigating, defending,
being a witness in or participating in (including on appeal) or preparing for
any of the foregoing, any Proceeding relating to any Indemnifiable Event.

          (d) "Indemnifiable Event" shall mean any event or occurrence that
takes place either prior to or after the execution of this Agreement, related to
the fact that the Indemnitee is or was a director or officer of the Company, or
is or was serving at the request of the Company as a director, officer, employee
or agent of another corporation or of a partnership, joint venture, trust or
other enterprise, including service with respect to employee benefit plans, or
by reason of anything done or not done by the Indemnitee in any such capacity.

          (e) "Proceeding" shall mean any threatened, pending or completed
action, suit, investigation or proceeding, and any appeal thereof, whether
civil, criminal, administrative or investigative and/or any inquiry or
investigation, whether conducted by the Company or any other party, that the
Indemnitee in good faith believes might lead to the institution of any such
action.

          (f) "Reviewing Party" shall mean any appropriate person or body
consisting of a member or members of the Company's Board or any other person or
body appointed by the Board (including the special independent counsel referred
to in Section 6) who is not a party to the particular Proceeding with respect to
which the Indemnitee is seeking indemnification.

          (g) "Voting Securities" shall mean any securities of the Company which
vote generally in the election of directors.

          2. INDEMNIFICATION. In the event the Indemnitee was or is a party to
or is involved (as a party, witness or otherwise) in any Proceeding by reason of
(or arising in part out of) an Indemnifiable Event, whether the basis of the
Proceeding is the Indemnitee's alleged action in an official capacity as a
director or officer or in any other capacity while serving as a director or
officer, the Company shall indemnify the Indemnitee to the fullest extent
permitted by the DGCL against any and all Expenses, liabilities and losses
(including judgments, fines, ERISA excise taxes or penalties, and amounts paid
or to be paid in settlement, and any interest, assessments or other charges
imposed thereon, and any federal, state, local or foreign taxes imposed on any
director or officer as a result of the actual or deemed receipt of any payments
under this Agreement) (collectively, "Liabilities") reasonably incurred or
suffered by such person in connection with such Proceeding. The Company shall
provide indemnification pursuant to this Section 2 as soon as practicable, but
in no event later than 30 days after it receives written demand from the
Indemnitee. Notwithstanding anything in this Agreement to the contrary and
except as provided in Section 5 below, the Indemnitee shall not be entitled to
indemnification pursuant to this Agreement (i) in connection with any Proceeding
initiated by the Indemnitee against the Company or any director or officer of
the Company unless the Company has joined in or consented to the initiation of
such Proceeding or (ii) on account of any suit in which judgment is rendered
against the Indemnitee pursuant to Section 16(b) of the Exchange Act for an
accounting of profits made from the purchase, sale or other transaction by the
Indemnitee of securities of the Company (or derivatives thereof).

          3. ADVANCEMENT OF EXPENSES. The Company shall advance Expenses to the
Indemnitee within 30 business days of such request (an "Expense Advance");
provided, however, that if required by applicable corporate laws, such Expenses
shall be advanced only

upon delivery to the Company of an undertaking by or on behalf of the Indemnitee
to repay such amount if it is ultimately determined that the Indemnitee is not
entitled to be indemnified by the Company; provided, further, that the Company
shall make such advances only to the extent permitted by applicable law.
Expenses incurred by the Indemnitee while not acting in his/her capacity as a
director or officer, including service with respect to employee benefit plans,
may be advanced upon such terms and conditions as the Board, in its sole
discretion, deems appropriate.

          4. REVIEW PROCEDURE FOR INDEMNIFICATION. Notwithstanding the
foregoing, (i) the obligations of the Company under Sections 2 and 3 above shall
be subject to the condition that the Reviewing Party shall not have determined
(in a written opinion, in any case in which the special independent counsel
referred to in Section 6 hereof is involved) that the Indemnitee would not be
permitted to be indemnified under applicable law and (ii) the obligation of the
Company to make an Expense Advance pursuant to Section 3 above shall be subject
to the condition that, if, when and to the extent that the Reviewing Party
determines that the Indemnitee would not be permitted to be so indemnified under
applicable law, the Company shall be entitled to be reimbursed by the Indemnitee
(who hereby agrees to reimburse the Company) for all such amounts theretofore
paid; provided, however, that if the Indemnitee has commenced legal proceedings
in a court of competent jurisdiction pursuant to Section 5 below to secure a
determination that the Indemnitee should be indemnified under applicable law,
any determination made by the Reviewing Party that the Indemnitee would not be
permitted to be indemnified under applicable law shall not be binding and the
Indemnitee shall not be required to reimburse the Company for any Expense
Advance until a final judicial determination is made with respect thereto (as to
which all rights of appeal therefrom have been exhausted or have lapsed). The
Indemnitee's obligation to reimburse the Company for Expense Advances pursuant
to this Section 4 shall be unsecured and no interest shall be charged thereon.
If there has not been a Change in Control, the Reviewing Party shall be selected
by the Board, and if there has been such a Change in Control, other than a
Change in Control which has been approved by a majority of the Company's Board
who were directors immediately prior to such Change in Control, the Reviewing
Party shall be the special independent counsel referred to in Section 6 hereof.

          5. ENFORCEMENT OF INDEMNIFICATION RIGHTS. If the Reviewing Party
determines that the Indemnitee substantively would not be permitted to be
indemnified in whole or in part under applicable law, or if the Indemnitee has
not otherwise been paid in full pursuant to Sections 2 and 3 above within 30
days after a written demand has been received by the Company, the Indemnitee
shall have the right to commence litigation in any court in the State of
Delaware having subject matter jurisdiction thereof and in which venue is proper
to recover the unpaid amount of the demand (an "Enforcement Proceeding") and, if
successful in whole or in part, the Indemnitee shall be entitled to be paid any
and all Expenses in connection with such Enforcement Proceeding. The Company
hereby consents to service of process for such Enforcement Proceeding and to
appear in any such Enforcement Proceeding. Any determination by the Reviewing
Party otherwise shall be conclusive and binding on the Company and the
Indemnitee.

          6. CHANGE IN CONTROL. The Company agrees that if there is a Change in
Control of the Company, other than a Change in Control which has been approved
by a majority of the Company's Board who were directors immediately prior to
such Change in Control, then with

respect to all matters thereafter arising concerning the rights of the
Indemnitee to indemnity payments and Expense Advances under this Agreement or
any other agreement or under applicable law or the Certificate of Incorporation
or Bylaws now or hereafter in effect relating to indemnification for
Indemnifiable Events, the Company shall seek legal advice only from special
independent counsel selected by the Indemnitee and approved by the Company,
which approval shall not be unreasonably withheld. Such special independent
counsel shall not have otherwise performed services for the Company or the
Indemnitee, other than in connection with such matters, within the last five
years. Such independent counsel shall not include any person who, under the
applicable standards of professional conduct then prevailing, would have a
conflict of interest in representing either the Company or the Indemnitee in an
action to determine the Indemnitee's rights under this Agreement. Such counsel,
among other things, shall render its written opinion to the Company and the
Indemnitee as to whether and to what extent the Indemnitee would be permitted to
be indemnified under applicable law. The Company agrees to pay the reasonable
fees of the special independent counsel referred to above and to indemnify fully
such counsel against any and all expenses (including attorneys' fees), claims,
liabilities and damages arising out of or relating to this Agreement or the
engagement of special independent counsel pursuant to this Agreement.

          7. PARTIAL INDEMNITY. If the Indemnitee is entitled under any
provision of this Agreement to indemnification by the Company for some or a
portion of the Expenses and Liabilities, but not, however, for all of the total
amount thereof, the Company shall nevertheless indemnify the Indemnitee for the
portion thereof to which the Indemnitee is entitled. Moreover, notwithstanding
any other provision of this Agreement, to the extent that the Indemnitee has
been successful on the merits or otherwise in defense of any or all Proceedings
relating in whole or in part to an Indemnifiable Event or in defense of any
issue or matter therein, including dismissal without prejudice, the Indemnitee
shall be indemnified against all Expenses incurred in connection therewith. In
connection with any determination by the Reviewing Party or otherwise as to
whether the Indemnitee is entitled to be indemnified hereunder, the burden of
proof shall be on the Company to establish that the Indemnitee is not so
entitled.

          8. NON-EXCLUSIVITY. The rights of the Indemnitee hereunder shall be in
addition to any other rights the Indemnitee may have under any statute,
provision of the Certificate of Incorporation or Bylaws, vote of stockholders or
disinterested directors or otherwise, both as to action in an official capacity
and as to action in another capacity while holding such office. To the extent
that a change in the DGCL permits greater indemnification by agreement than
would be afforded currently under the Company's Certificate of Incorporation and
Bylaws and this Agreement, it is the intent of the parties hereto that the
Indemnitee shall enjoy by this Agreement the greater benefits so afforded by
such change.

          9. LIABILITY INSURANCE. To the extent the Company maintains an
insurance policy or policies providing directors' and officers' liability
insurance, the Indemnitee shall be covered by such policy or policies, in
accordance with its or their terms, to the maximum extent of the coverage
available for any director or officer of the Company.

          10. SETTLEMENT OF CLAIMS. The Company shall not be liable to indemnify
the Indemnitee under this Agreement (a) for any amounts paid in settlement of
any action or claim effected without the Company's written consent, which
consent shall not be unreasonably

withheld; or (b) for any judicial award if the Company was not given a
reasonable and timely opportunity, at its expense, to participate in the defense
of such action.

          11. NO PRESUMPTION. For purposes of this Agreement, to the fullest
extent permitted by law, the termination of any Proceeding, action, suit or
claim, by judgment, order, settlement (whether with or without court approval)
or conviction, or upon a plea of nolo contendere, or its equivalent, shall not
create a presumption that the Indemnitee did not meet any particular standard of
conduct or have any particular belief or that a court has determined that
indemnification is not permitted by applicable law.

          12. PERIOD OF LIMITATIONS. No legal action shall be brought and no
cause of action shall be asserted by or on behalf of the Company or any
affiliate of the Company against the Indemnitee, the Indemnitee's spouse, heirs,
executors or personal or legal representatives after the expiration of two years
from the date of accrual of such cause of action, or such longer period as may
be required by state law under the circumstances, and any claim or cause of
action of the Company or its affiliate shall be extinguished and deemed released
unless asserted by the timely filing of a legal action within such period;
provided, however, that if any shorter period of limitations is otherwise
applicable to any such cause of action, such shorter period shall govern.

          13. CONSENT AND WAIVER BY THIRD PARTIES. The Indemnitee hereby
represents and warrants that he or she has obtained all waivers and/or consents
from third parties which are necessary for his or her employment with the
Company on the terms and conditions set forth herein and to execute and perform
this Agreement without being in conflict with any other agreement, obligation or
understanding with any such third party. The Indemnitee represents that he or
she is not bound by any agreement or any other existing or previous business
relationship which conflicts with, or may conflict with, the performance of his
or her obligations hereunder or prevent the full performance of his or her
duties and obligations hereunder.

          14. AMENDMENT OF THIS AGREEMENT. No supplement, modification or
amendment of this Agreement shall be binding unless executed in writing by both
of the parties hereto. No waiver of any of the provisions of this Agreement
shall be deemed or shall constitute a waiver of any other provisions hereof
(whether or not similar), nor shall such waiver constitute a continuing waiver.
Except as specifically provided herein, no failure to exercise or any delay in
exercising any right or remedy hereunder shall constitute a waiver thereof.

          15. SUBROGATION. In the event of payment under this Agreement, the
Company shall be subrogated to the extent of such payment to all of the rights
of recovery of the Indemnitee, who shall execute all papers required and shall
do everything that may be necessary to secure such rights, including the
execution of such documents necessary to enable the Company effectively to bring
suit to enforce such rights.

          16. NO DUPLICATION OF PAYMENTS. The Company shall not be liable under
this Agreement to make any payment in connection with any claim made against
Indemnitee to the extent the Indemnitee has otherwise actually received payment
(under any insurance policy, Bylaw, vote, agreement or otherwise) of the amounts
otherwise indemnifiable hereunder.

          17. BINDING EFFECT. This Agreement shall be binding upon and inure to
the benefit of and be enforceable by the parties hereto and their respective
successors, assigns, including any direct or indirect successor by purchase,
merger, consolidation or otherwise to all or substantially all of the business
and/or assets of the Company, spouses, heirs and personal and legal
representatives. The Company shall require and cause any successor (whether
direct or indirect by purchase, merger, consolidation or otherwise) to all,
substantially all, or a substantial part, of the business and/or assets of the
Company, by written agreement in form and substance satisfactory to the
Indemnitee, expressly to assume and agree to perform this Agreement in the same
manner and to the same extent that the Company would be required to perform if
no such succession had taken place. This Agreement shall continue in effect
regardless of whether the Indemnitee continues to serve as a director or officer
of the Company or of any other enterprise at the Company's request.

          18. SEVERABILITY. The provisions of this Agreement shall be severable
in the event that any of the provisions hereof (including any provision within a
single section, paragraph or sentence) is held by a court of competent
jurisdiction to be invalid, void or otherwise unenforceable, and the remaining
provisions shall remain enforceable to the fullest extent permitted by law.
Furthermore, to the fullest extent possible, the provisions of this Agreement
(including, without limitation, each portion of this Agreement containing any
provision held to be invalid, void or otherwise unenforceable, that is not
itself invalid, void or unenforceable) shall be construed so as to give effect
to the intent manifested by the provision held invalid, illegal or
unenforceable.

          19. GOVERNING LAW. This Agreement shall be governed by and construed
and enforced in accordance with the laws of the State of Delaware applicable to
contracts made and to be performed in such State without giving effect to the
principles of conflicts of laws.

          20. COUNTERPARTS. This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

          21. NOTICES. All notices, demands, and other communications required
or permitted hereunder shall be made in writing and shall be deemed to have been
duly given if delivered by hand, against receipt, or mailed, postage prepaid,
certified or registered mail, return receipt requested, and addressed to the
Company at:

                          BioMimetics Theraputics, Inc.
                          389 Nichol Mill Lane
                          Franklin, TN 37067
                          Attention President

                  and to the Indemnitee at:

                          ----------------------------
                          ----------------------------
                          ----------------------------
                          ----------------------------

         Notice of change of address shall be effective only when done in
accordance with this Section. All notices complying with this Section shall be
deemed to have been received on the date of delivery or on the third business
day after mailing.

         IN WITNESS WHEREOF, the parties hereto have duly executed and delivered
this Agreement as of the day first set forth above.

                  THE COMPANY

                  BIOMIMETICS THERAPEUTICS, INC.

                  By:________________________________________________________

                  Name:______________________________________________________

                  Title:_____________________________________________________

                  INDEMNITEE:

                  ___________________________________________________________

                   Signature

                  Print Name:________________________________________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00097-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00097-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00097-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00097-of-00352.parquet"}]]